An Open Label Study of the Effects of Eculizumab in CD59 Deficiency

Trial Profile

An Open Label Study of the Effects of Eculizumab in CD59 Deficiency

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolysis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results of this and one other study presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 18 Oct 2016 New trial record
    • 29 Aug 2016 According to the results published in the Annals of Neurology, the study was initially designed to include 8 months of eculizumab treatment. After 8 months the study seemed to be life saving and hence was extended to 2 years
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top